# Infinimmune

> Infinimmune is an Alameda biotechnology company that discovers antibodies directly from human memory B cells, refines them with computational models and laboratory work, and develops its own inflammatory disease drugs alongside discovery partnerships.

- **Founded:** 2022
- **Headquarters:** Alameda, United States
- **Founders:** Wyatt McDonnell (CEO and co-founder), Mike Gibbons (Chief Scientific Officer and co-founder), Katie Pfeiffer (Chief Technology Officer and co-founder), Lance Hepler (Chief Information Officer and co-founder), David Jaffe (Infinimmune Fellow and co-founder)
- **Products:** Complete Human, Anthrobody, GLIMPSE-1, IFX-101, IFX-201
- **Notable:** Raised $75 million Series A in August 2026, for $87 million in two disclosed named rounds., Signed a multi-target Merck antibody discovery agreement in March 2026., Launched GLIMPSE-1 and published a 2025 preprint.

## Products & services

- **Complete Human** — Captures full, naturally paired antibody sequences from human B cells.
- **Anthrobody** — Screens human memory B cells for antigen-specific antibodies.
- **GLIMPSE-1** — Human-sequence-trained antibody language model for candidate engineering.
- **IFX-101** — Preclinical IL-22 antibody for moderate-to-severe atopic dermatitis.
- **IFX-201** — Preclinical IL-13 antibody for moderate-to-severe atopic dermatitis.
- **IFX-301** — Preclinical APRIL program for IgA nephropathy.
- **IFX-401** — Preclinical IL-17F program for ulcerative colitis.

## Achievements

- Raised $75 million Series A in August 2026, for $87 million in two disclosed named rounds.
- Signed a multi-target Merck antibody discovery agreement in March 2026.
- Launched GLIMPSE-1 and published a 2025 preprint.
- Advanced IFX-101 and IFX-201 toward first-in-human studies planned for 2027.

## Latest updates

- **2026-08** — Closed $75 million Series A and outlined first-in-human study plans for 2027.
- **2026-03** — Announced multi-target Merck collaboration with potential aggregate payments up to approximately $838 million.
- **2025-09** — Announced Immunome discovery and KBI Biopharma manufacturing collaborations.
- **2025-06** — Launched GLIMPSE-1 and published a bioRxiv preprint.

## Links

- Website: https://www.infinimmune.com/
- LinkedIn: https://www.linkedin.com/company/infinimmune
- Twitter/X: https://twitter.com/infinimmune

---

Profile page: https://yespress.io/infinimmune
Published by YesPress — https://yespress.io
Last updated: 2026-09-30